About Orszagos Onkologiai Intezet "B" Belgyogyaszati osztaly
Top Sponsors
Top Collaborators
Trials By Phase
Recruitment Status
Top Conditions
Intervention Types
Top Intervention Names
Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
14
Puma Biotechnology, Inc.
4
Pfizer
3
Helsinn Healthcare SA
1
Clinical Trials at Orszagos Onkologiai Intezet "B" Belgyogyaszati osztaly
During the past decade, Orszagos Onkologiai Intezet "B" Belgyogyaszati osztaly conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 14 clinical trials were completed, i.e. on
average, 175% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 4 clinical trials were completed. i.e. 133.3%
of trials that started reached the finish line.
A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer
2011-11-08
2028-11-30
Active, not recruiting
4,804
Clinical Trials Sponsors and Collaborators
In terms of collaborators to trials, out of the total clinical trials conducted in "Orszagos Onkologiai Intezet "B" Belgyogyaszati osztaly"
#1 collaborator was "Breast International Group" with 1 trials as a collaborator, "Foundation Medicine, Inc." with 1 trials as a collaborator, "Genentech, Inc." with 1 trials as a collaborator and "Parexel" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were
collaborators in the rest 4 trials.
Clinical Trials Conditions at Orszagos Onkologiai Intezet "B" Belgyogyaszati osztaly
According to Clinical.Site data, the most researched conditions in "Orszagos Onkologiai Intezet "B" Belgyogyaszati osztaly" are
"Breast Cancer" (11 trials), "Advanced Breast Cancer" (1 trials), "Basal Cell Carcinoma" (1 trials), "Breast Neoplasms" (1 trials) and "Cancer of Unknown Primary Site" (1 trials). Many other conditions were trialed in "Orszagos Onkologiai Intezet "B" Belgyogyaszati osztaly" in a lesser frequency.
Most popular intervention types in "Orszagos Onkologiai Intezet "B" Belgyogyaszati osztaly" are "Drug" (21 trials), "Other" (4 trials) and "Combination Product" (1 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (8 trials), "Trastuzumab" (6 trials), "Capecitabine" (5 trials), "Pertuzumab" (5 trials) and "Atezolizumab" (4 trials). Other intervention names were less common.
Clinical Trials Genders at Orszagos Onkologiai Intezet "B" Belgyogyaszati osztaly
The vast majority of trials in "Orszagos Onkologiai Intezet "B" Belgyogyaszati osztaly" are
16 trials for "All" genders and 6 trials for "Female" genders.
Clinical Trials Status at Orszagos Onkologiai Intezet "B" Belgyogyaszati osztaly
Currently, there are NaN active trials in "Orszagos Onkologiai Intezet "B" Belgyogyaszati osztaly".
undefined are not yet recruiting,
3 are recruiting,
4 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 13 completed trials in Orszagos Onkologiai Intezet "B" Belgyogyaszati osztaly,
undefined suspended trials,
and 2 terminated clinical trials to date.
Out of the total trials that were conducted in Orszagos Onkologiai Intezet "B" Belgyogyaszati osztaly, 1 "Phase 1"
clinical trials were conducted, 7 "Phase 2" clinical
trials and 15 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".